Protein / Drugs / Drug / Clinical / Therapeutics / Biotech / BioTech / Boston / Boston blog main / Boston top stories / National blog main / Arkin Bio Ventures / clinical trials / coronavirus / Cowen Healthcare Investments / Financing / Foresite Capital / Global Health Sciences Fund / IPO / Keros Therapeutics / Life Sciences / Massachusetts General Hospital / Medison Pharma / National Center for Advancing Translational Sciences / National Institutes of Health / Orbimed / Partners Innovation Fund / Pontifax / Startup / Venrock / Venture Capital

Keros Outlines IPO Plans Amid Markets Rocked by Coronavirus Pandemic

Posted On: Mar 24, 2020   |   Posted By: Xconomy

Keros Outlines IPO Plans Amid Markets Rocked by Coronavirus Pandemic

Keros Therapeutics, a biotech which raised more than $50 million this month in venture capital, is now looking to tap the public markets for additional cash amid a time of historic tumult. The Lexington, MA-based company, is a clinical-stage biotech that aims to develop new treatments for patients with blood and musculoskeletal disorders by developing drugs that inhibit a family of proteins called TGF-beta. TGF-beta signaling pathways play a key role in regulating red blood cell and platelet production as well growth, repair, and maintenance of muscle and bone. In its prospectus , Keros said it would use the IPO cash...

Continue reading ...